Loading...
Market
Next clinical milestone for Vyvgart Hytrulo by end of 2024?
5
Resolution / Starting Odds
Phase II success for new indication • 33%
Phase III success for current indications • 33%
New FDA approval for different indication • 34%
Argenx's official announcements or clinical trial registries
Story
Argenx's Vyvgart Hytrulo Shot Gains Second FDA Approval for CIDP with Halozyme's ENHANZE
Jun 21, 2024, 09:10 PM
Argenx's Vyvgart Hytrulo shot has received its second US FDA approval to treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare nervous system disorder. This approval marks a significant milestone for the biotechnology firm, which has faced a series of setbacks. The Vyvgart Hytrulo shot is co-formulated with Halozyme's ENHANZE technology. This label expansion into CIDP adds to Argenx's growth prospects ahead of more clinical milestones anticipated in 2024.
View original story
Similar markets
FDA approval • 25%
New clinical trial results • 25%
Partnership with another company • 25%
No major announcement • 25%
Positive efficacy and safety • 25%
Positive efficacy, negative safety • 25%
Negative efficacy • 25%
Inconclusive • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Regulatory approval submission • 25%
No significant milestone • 25%
